Protalix Narrows H1 Loss on Strong Revenue Growth, Q2 Turns Profit

TL;DR

**PLX is showing signs of life with revenue growth and a profitable quarter, but watch that R&D spend and ongoing equity dilution.**

AI Summary

Protalix BioTherapeutics, Inc. (PLX) reported a significant increase in total revenue for the six months ended June 30, 2025, reaching $25.77 million, up from $17.22 million in the same period of 2024, a 49.6% increase. This was primarily driven by a rise in revenues from selling goods to $25.44 million from $16.98 million. Despite this revenue growth, the company posted a net loss of $3.46 million for the six-month period, an improvement from the $6.80 million net loss in the prior year. However, for the three months ended June 30, 2025, PLX achieved a net income of $0.16 million, a notable turnaround from a $2.20 million net loss in Q2 2024. Research and development expenses increased substantially to $9.47 million for the six months, up from $5.85 million, reflecting increased investment in product candidates like PRX-115 and PRX-119. The company's cash and cash equivalents decreased to $17.90 million as of June 30, 2025, from $19.76 million at December 31, 2024, but management believes current liquidity is sufficient for at least 12 months. Strategic developments include the continued commercialization of Elfabrio and Elelyso, and an amendment to the Sales Agreement in March 2025, increasing available common stock for sale by $20.0 million, with $15.7 million remaining as of June 30, 2025.

Why It Matters

Protalix's improved financial performance, particularly the Q2 2025 net income, signals potential progress in its commercialization efforts for Elfabrio and Elelyso, which could attract new investors. The substantial increase in R&D spending indicates a commitment to pipeline expansion, crucial for long-term growth in the competitive biopharmaceutical market, especially with new candidates like PRX-115 and PRX-119. For employees, this suggests job stability and continued investment in innovation. Customers benefit from the ongoing development of treatments for rare diseases like Fabry and Gaucher. However, the reliance on equity sales for financing and the geopolitical risks in Israel remain key considerations for market participants.

Risk Assessment

Risk Level: medium — The company reported a net loss of $3.46 million for the six months ended June 30, 2025, and a decrease in cash and cash equivalents to $17.90 million from $19.76 million. While management believes current liquidity is sufficient for 12 months, the company continues to incur significant R&D expenditures ($9.47 million for H1 2025) and relies on equity sales, having $15.7 million in common stock available under its Sales Agreement as of June 30, 2025, indicating potential future dilution.

Analyst Insight

Investors should monitor Protalix's ability to sustain profitability beyond Q2 2025 and the commercial uptake of Elfabrio. Evaluate the impact of increased R&D on future pipeline success and watch for further equity dilution from the remaining $15.7 million under the Sales Agreement, as this could affect share value.

Financial Highlights

debt To Equity

0.57

revenue

$25.77M

operating Margin

-11.55%

total Assets

$78.49M

total Debt

$28.58M

net Income

$0.16M

eps

$0.00

gross Margin

44.7%

cash Position

$17.90M

revenue Growth

+49.6%

Revenue Breakdown

Key Numbers

• $25.77M — Total Revenue (H1 2025) (Increased 49.6% from $17.22 million in H1 2024)
• $15.66M — Total Revenue (Q2 2025) (Increased from $13.47 million in Q2 2024)
• $0.16M — Net Income (Q2 2025) (Turnaround from a $2.20 million net loss in Q2 2024)
• $3.46M — Net Loss (H1 2025) (Improved from a $6.80 million net loss in H1 2024)
• $9.47M — R&D Expenses (H1 2025) (Increased from $5.85 million in H1 2024)
• $17.90M — Cash and Cash Equivalents (June 30, 2025) (Decreased from $19.76 million at December 31, 2024)
• $15.7M — Remaining Common Stock for Sale (Available under the Sales Agreement as of June 30, 2025)
• 79,732,115 — Shares Outstanding (August 1, 2025) (Reflects recent equity issuances)

Key Players & Entities

• Protalix BioTherapeutics, Inc. (company) — registrant
• H.C. Wainwright & Co., LLC (company) — sales agent for common stock
• Pfizer Inc. (company) — licensee for Elelyso
• Chiesi Farmaceutici S.p.A. (company) — partner for Elfabrio
• Fundao Oswaldo Cruz (Fiocruz) (company) — licensee for Elelyso in Brazil
• Elfabrio (pegunigalsidase alfa) (product) — approved treatment for Fabry disease
• Elelyso (taliglucerase alfa) (product) — approved treatment for Gaucher disease
• PRX-115 (product) — product candidate for uncontrolled gout
• PRX-119 (product) — product candidate for NETs-related diseases
• U.S. Food and Drug Administration (FDA) (regulator) — approved Elfabrio and Elelyso

FAQ

Risk Factors

• Liquidity and Going Concern [medium — financial]: The company's cash and cash equivalents decreased to $17.90 million as of June 30, 2025, from $19.76 million at December 31, 2024. While management believes current liquidity is sufficient for at least 12 months, a continued decrease in cash could pose a risk.
• Research and Development Investment [medium — operational]: R&D expenses increased substantially to $9.47 million for the six months ended June 30, 2025, from $5.85 million in the prior year. Continued investment in product candidates like PRX-115 and PRX-119 is crucial but also represents a significant cash outflow.
• Commercialization of Products [medium — market]: The company's success relies on the continued commercialization of Elfabrio and Elelyso. Market acceptance, competition, and reimbursement policies can significantly impact revenue generation.
• Equity Financing Dependence [low — financial]: The company amended its Sales Agreement in March 2025, increasing available common stock for sale by $20.0 million, with $15.7 million remaining as of June 30, 2025. Reliance on equity sales for funding can dilute existing shareholders.
• Regulatory Approvals and Compliance [high — regulatory]: As a biopharmaceutical company, Protalix is subject to stringent regulatory oversight for drug development, approval, and manufacturing. Delays or failures in regulatory processes can severely impact product timelines and market access.

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and stringent regulatory hurdles. Protalix operates in this environment, focusing on the development and commercialization of protein-based therapeutics. Key trends include increasing investment in novel drug modalities and a growing demand for treatments for rare diseases.

Regulatory Implications

Protalix faces significant regulatory risks associated with the development, approval, and commercialization of its drug candidates. Compliance with FDA and other global regulatory bodies is paramount. Any delays or setbacks in regulatory processes can have a material impact on the company's financial performance and future prospects.

What Investors Should Do

1. Monitor R&D spending and pipeline progress
2. Analyze revenue drivers and commercialization success
3. Assess liquidity and cash burn rate

Key Dates

• 2025-06-30: End of Q2 2025 and H1 2025 reporting period — Provided updated financial performance, including a net income of $0.16M for Q2 2025 and a reduced net loss of $3.46M for H1 2025.
• 2025-03-XX: Amendment to Sales Agreement — Increased available common stock for sale by $20.0 million, providing potential for additional capital infusion.

Glossary

Revenues from Selling Goods

Revenue generated from the sale of manufactured pharmaceutical products. (This is the primary source of revenue for Protalix, showing significant growth in the reported periods.)

Research and Development Expenses

Costs incurred in the process of discovering, developing, and testing new drugs or therapies. (A significant expense for Protalix, indicating investment in future product pipelines.)

Net Income (Loss)

The profit or loss remaining after all expenses, taxes, and interest have been deducted from total revenue. (Shows the company's profitability, with a notable turnaround to net income in Q2 2025.)

Cash and cash equivalents

Highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. (Indicates the company's short-term liquidity and ability to meet immediate obligations.)

Sales Agreement

An agreement allowing a company to sell shares of its common stock over time at prevailing market prices. (Protalix utilizes this to raise capital, with an amendment increasing the potential amount of stock that can be sold.)

Year-Over-Year Comparison

Compared to the prior year's six-month period, Protalix BioTherapeutics has demonstrated robust revenue growth of 49.6%, driven by increased sales of goods. This revenue expansion has helped narrow the net loss from $6.80 million to $3.46 million. However, research and development expenses have also risen significantly, indicating increased investment in pipeline development. The company's cash position has slightly decreased, but remains a key focus for liquidity management.

Key Financial Figures

• $0.001 — nge on which registered Common stock, $0.001 par value PLX NYSE American Indic
• $1 — Represents an amount equal to less than $1. (1) Common stock, $ 0.001 par value;

Filing Documents

• plx-20250630x10q.htm (10-Q) — 1040KB
• plx-20250630xex31d1.htm (EX-31.1) — 12KB
• plx-20250630xex31d2.htm (EX-31.2) — 12KB
• plx-20250630xex32d1.htm (EX-32.1) — 7KB
• plx-20250630xex32d2.htm (EX-32.2) — 7KB
• plx-20250630x10q005.jpg (GRAPHIC) — 83KB
• plx-20250630x10q006.jpg (GRAPHIC) — 57KB
• plx-20250630x10q007.jpg (GRAPHIC) — 51KB
• plx-20250630x10q008.jpg (GRAPHIC) — 37KB
• plx-20250630x10q009.jpg (GRAPHIC) — 55KB
• plx-20250630x10q010.jpg (GRAPHIC) — 39KB
• 0001558370-25-011471.txt ( ) — 5048KB
• plx-20250630.xsd (EX-101.SCH) — 28KB
• plx-20250630_cal.xml (EX-101.CAL) — 43KB
• plx-20250630_def.xml (EX-101.DEF) — 104KB
• plx-20250630_lab.xml (EX-101.LAB) — 214KB
• plx-20250630_pre.xml (EX-101.PRE) — 175KB
• plx-20250630x10q_htm.xml (XML) — 597KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements Condensed Consolidated Balance Sheets (Unaudited) – As of June 30, 2025 and December 31, 2024 2 Condensed Consolidated Statements of Operations (Unaudited) – For the Six and Three Months Ended June 30, 2025 and 2024 3 Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) – For the Six and Three Months Ended June 30, 2025 and 2024 4 Condensed Consolidated Statements of Cash Flows (Unaudited) – For the Six Months Ended June 30, 2025 and 2024 5 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 33 Item 4.

Controls and Procedures

Controls and Procedures 33

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 35 Item 1A.

Risk Factors

Risk Factors 35 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 35 Item 3. Defaults Upon Senior Securities 35 Item 4. Mine Safety Disclosures 35 Item 5. Other Information 35 Item 6. Exhibits 35

Signatures

Signatures 37 Table of Contents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements PROTALIX BIOTHERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (U.S. dollars in thousands) (Unaudited) June 30, 2025 December 31, 2024 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 17,895 $ 19,760 Short-term bank deposits 15,503 15,070 Accounts receivable – Trade 9,443 2,909 Other assets 1,513 1,096 Inventories 21,131 21,243 Total current assets $ 65,485 $ 60,078 NON-CURRENT ASSETS: Funds in respect of employee rights upon retirement $ 520 $ 462 Property and equipment, net 4,746 4,591 Deferred income tax asset 2,738 2,856 Operating lease right of use assets 4,997 5,430 Total assets $ 78,486 $ 73,417 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable and accruals: Trade $ 6,689 $ 4,533 Other 15,930 19,588 Operating lease liabilities 1,472 1,500 Total current liabilities $ 24,091 $ 25,621 LONG TERM LIABILITIES: Liability for employee rights upon retirement $ 615 $ 559 Operating lease liabilities 3,877 4,026 Total long term liabilities $ 4,492 $ 4,585 Total liabilities $ 28,583 $ 30,206 COMMITMENTS STOCKHOLDERS' EQUITY 49,903 43,211 Total liabilities and stockholders' equity $ 78,486 $ 73,417 The accompanying notes are an integral part of the condensed consolidated financial statements. 2 Table of Contents PROTALIX BIOTHERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (U.S. dollars in thousands, except share and per share data) (Unaudited) Six Months Ended Three Months Ended June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024 REVENUES FROM SELLING GOODS $ 25,435 $ 16,981 $ 15,440 $ 13,304 REVENUES FROM LICENSE AND R&D SERVICES 336 241 218 170 TOTAL REVENUE 25,771 17,222 15,658 13,474 COST OF GOODS SOLD ( 14,050 ) ( 12,058 ) ( 5,870 ) ( 9,456 ) RESEARCH AND DEVELOPMENT EXPENSES

View Full Filing

View this 10-Q filing on SEC EDGAR